Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2022-01-27
- Target Recruit Count
- 66
- Registration Number
- NCT05113290
- Locations
- 🇨🇳
Tangdu Hospital, Xi'an, Shaanxi, China
🇨🇳The First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an, Shaanxi, China
🇨🇳Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- HonorHealth Research Institute
- Target Recruit Count
- 12
- Registration Number
- NCT05068752
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
Immunotherapy for Advanced Liver Cancer
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Mirror Biologics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05033522
- Locations
- 🇲🇾
Sultan Ismail Hospital, Johor Bahru, Johor, Malaysia
🇲🇾Columbia Asia Bukit Rimau, Shah Alam, Selangor Darul Ehsan, Malaysia
🇲🇾Sultanah Bahiyah Hospital, Alor Setar, Kedah, Malaysia
TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC
- Conditions
- BCLC Stage C Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 20
- Registration Number
- NCT04992143
- Locations
- 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
- Conditions
- Advanced Hepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT04985136
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04926532
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, China
Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD MutationHematopoietic Stem Cell TransplantationAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 456
- Registration Number
- NCT04788420
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
- Conditions
- Unresectable Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 554
- Registration Number
- NCT04770896
- Locations
- 🇨🇳
Fujian Provincial Hospital, Fuzhou City, China
🇦🇹Medizinische Universität Innsbruck, Innsbruck, Austria
🇦🇹Uniklinikum Salzburg, LKH, Salzburg, Austria
A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 335
- Registration Number
- NCT04763408
- Locations
- 🇺🇸
California Liver Research Institute, Pasadena, California, United States
🇩🇪Eisai Trial Site #2, Berlin, Germany
🇩🇪Eisai Trial Site #6, Munich, Germany
Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- Conditions
- Advanced Hepatocellular Carcinoma (HCC)
- Interventions
- Combination Product: Toripalimab combined with Bevacizumab
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 326
- Registration Number
- NCT04723004
- Locations
- 🇨🇳
Jilin Guowen Hospital, Changchun, Jilin, China
🇨🇳The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.